Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Zoladex

(Goserelin)

ApprovedSmall molecule

TTerSera Therapeutics LLC

Goserelin is used to treat advanced prostate cancer in men and breast cancer in women by lowering hormone levels. It's also used to help manage endometriosis and uterine fibroids in women.[2] Zoladex is currently approved and in use across 25 indications[4].[1]

Zoladex is one of 391 small molecule programs targeting Breast Cancer. It is currently in Approved.

25

Indications

106

Total Trials

30

Active Trials

390

Competitors

2

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Breast CancerCompleted

Breast NeoplasmsRecruiting

Hodgkins LymphomaApproved

InfertilityApproved

Premature Ovarian InsufficiencyApproved

AdenomyosisApproved

Salivary Gland CancerApproved

Breast NeoplasmApproved

Breast CarcinomaApproved

Ovarian DysfunctionApproved

Breast CancerPhase 3

Completed

Breast NeoplasmsPhase 2

Recruiting

Hodgkins LymphomaApproved

Approved

InfertilityApproved

Approved

Premature Ovarian InsufficiencyApproved

Approved

AdenomyosisApproved

Approved

Salivary Gland CancerApproved

Approved

Breast NeoplasmApproved

Approved

Breast CarcinomaApproved

Approved

Ovarian DysfunctionApproved

Approved

Showing 10 of 25 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Zoladex

TTerSera Therapeutics LLC

Adenocard

Zolymbus

MS Contin

HHikma Pharmaceuticals LLC

Duragesic-100

MS Contin

HHikma Pharmaceuticals LLC

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Acupan

YYonsei University

Chantix

PPrism Pharmaceuticals

Nubain

AAultman Health Foundation

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Breast Cancer

NCT05594095

Q1 2027

Phase 2Recruiting

Hormone Therapy

NCT05720260

Q2 2027

Phase 2Active, not recruiting

Breast Neoplasms

NCT05607004

Phase 3Active, not recruiting

Anatomic Stage III Breast Cancer AJCC V8

NCT02115282

Q3 2027

PreclinicalActive, not recruiting

Prostate Adenocarcinoma

NCT05003752

ApprovedRecruiting

Musculoskeletal Injury

NCT06455969

Clinical

Trials by Indication[1]

Breast Cancer42 trials

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT01723774·84 enrolled

Neoadjuvant Treatment of Breast Cancer

Not yet recruiting·NNational Institute of Oncology, Hungary··NCT05131893·300 enrolled

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

Unknown status·—··NCT05800197·300 enrolled

Show 39 more trials

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT03007979·55 enrolled

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01205685·11 enrolled

Everolimus trIal for Advanced prememopausaL Breast Cancer Patients

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT02313051·200 enrolled

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting·FFudan University·Phase 2·NCT05582499·716 enrolled

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Completed·PPalleos Healthcare GmbH·Phase 2·NCT03272477·257 enrolled

Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer

Completed·PPeking Union Medical College Hospital·Phase 3·NCT02483767·98 enrolled

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02586675·7 enrolled

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT03839823·222 enrolled

Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 3·NCT00429403·1 enrolled

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT03096847·502 enrolled

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting·FFudan University·Phase 2·NCT05594095·620 enrolled

Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer

Terminated·UUniversity of Washington·Phase 2·NCT00498901·1 enrolled

The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer

Unknown status·—·Phase 2·NCT02072512·180 enrolled

Zoladex Plus Tamoxifen in Breast Cancer

Completed·ZZhejiang Cancer Hospital·N/A·NCT00827307·100 enrolled

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

Terminated· Novartis logo

Novartis·Phase 2·NCT04862143·2 enrolled

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Completed·JJapan Breast Cancer Research Group·Phase 2·NCT01989780·160 enrolled

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01240941

PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer

Unknown status·—·Phase 2·NCT02917005·160 enrolled

Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea

Unknown status·PPeking Union Medical College Hospital·Phase 3·NCT02132390·300 enrolled

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Completed· Novartis logo

Novartis·Phase 1·NCT02333370·88 enrolled

Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01013506

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

Terminated·WWashington University School of Medicine·Phase 2·NCT02907918·26 enrolled

Neoadjuvant Goserelin for Triple Negative Breast Cancer

Unknown status·KKasr El Aini Hospital·Phase 2·NCT03444025·180 enrolled

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Terminated· Sanofi logo

Sanofi·Phase 3·NCT04478266·1,068 enrolled

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Completed· Novartis logo

Novartis·Phase 2·NCT03056755·383 enrolled

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Recruiting·UUniversity of Chicago·Phase 2·NCT06348134·74 enrolled

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT00432172·189 enrolled

MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 1·NCT01240928

PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Active, not recruiting·NNational Cancer Center, Japan·Phase 3·NCT03423199·180 enrolled

Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole

Completed·UUniversity Hospital, Akershus·Phase 2·NCT05163106·85 enrolled

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT03822468·376 enrolled

Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer

Completed·KKing Faisal Specialist Hospital & Research Center·Phase 3·NCT01530607·416 enrolled

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Recruiting·YYale University·Phase 2·NCT06953882·140 enrolled

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

Completed·SStanford University·Phase 2·NCT00186121·35 enrolled

Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

Completed·IInternational Cancer Research Group, United Arab Emirates·Phase 3·NCT03447132·354 enrolled

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT02278120·672 enrolled

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Completed·NNSABP Foundation Inc·Phase 2·NCT03628066·24 enrolled

Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Recruiting·WWashington University School of Medicine·Phase 2·NCT02476786·50 enrolled

Phase II Randomized, Double-blind, Placebo-controlled Study of LEE011(Ribociclib) or Placebo in Combination With Endocrine Therapy for the Treatment of Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer, Including a Subset With Pharmacokinetic Analysis.

Completed· Novartis logo

Novartis·Phase 2·NCT03671330·327 enrolled

Prostate Cancer28 trials

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Completed· Ferring logo

Ferring·Phase 3·NCT00833248·246 enrolled

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer

Terminated·NNCIC Clinical Trials Group·Phase 3·NCT00651326·48 enrolled

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02430480·39 enrolled

Show 25 more trials

Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00004635·159 enrolled

Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

Completed· Ferring logo

Ferring·Phase 3·NCT00884273·182 enrolled

A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer

Completed· Astellas logo

Astellas·Phase 3·NCT01964170·234 enrolled

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 3·NCT00388804·39 enrolled

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01377389·30 enrolled

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00631527·19 enrolled

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Unknown status·WWonju Severance Christian Hospital·Phase 4·NCT04248621·164 enrolled

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

Completed·SSWOG Cancer Research Network·Phase 3·NCT00004124·983 enrolled

Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer

Withdrawn·EEastern Cooperative Oncology Group·Phase 2·NCT00771017

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00002633·361 enrolled

Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002889·180 enrolled

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01750398·33 enrolled

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

Completed·UUniversity of Nebraska·Phase 1·NCT00482807·9 enrolled

Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer

Completed·IInstituto do Cancer do Estado de São Paulo·Phase 2·NCT02789878·64 enrolled

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00003653·1,386 enrolled

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Completed· Ferring logo

Ferring·Phase 3·NCT01744366·285 enrolled

Tecemotide (L-BLP25) in Prostate Cancer

Completed· EMD Serono logo

EMD Serono·Phase 2·NCT01496131·28 enrolled

Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer

Completed·UUniversity of Washington·Phase 2·NCT00769795·29 enrolled

Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Terminated· Ferring logo

Ferring·Phase 3·NCT00831233·42 enrolled

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03860987·12 enrolled

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Completed· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 2·NCT01252693·203 enrolled

Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

Recruiting·XXijing Hospital·Phase 2·NCT06575257·80 enrolled

Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer

Recruiting·NNational Taiwan University Hospital·N/A·NCT04894188·38 enrolled

Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT04356430·75 enrolled

FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer

Unknown status·TTampere University·Phase 4·NCT00293670·573 enrolled

Prostate Adenocarcinoma5 trials

Prostate Adenocarcinoma TransCutaneous Hormones

Unknown status·UUniversity College, London·Phase 3·NCT00303784·2,200 enrolled

Hypo-Combi Trial: Combined Hypofractionated External Beam Radiation Therapy (EBRT) Plus Interstitial High-Dose-Rate Brachytherapy (HDR-BT) Boost for Intermediate/High Risk Prostate Cancer

Active, not recruiting·GGerman Oncology Center, Cyprus·Preclinical·NCT05003752·40 enrolled

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

Active, not recruiting·NNRG Oncology·Preclinical·NCT03070886·612 enrolled

Show 2 more trials

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Active, not recruiting·NNRG Oncology·Phase 3·NCT04513717·2,753 enrolled

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Active, not recruiting·NNRG Oncology·Phase 3·NCT05050084·2,050 enrolled

Metastatic Prostate Cancer3 trials

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed· Pfizer logo

Pfizer··NCT05701007·1,083 enrolled

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00028769·41 enrolled

CMAB vs IMAB in Metastatic Prostate Cancer

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 4·NCT00255268·15 enrolled

Premenopausal2 trials

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 3·NCT00309478·1,099 enrolled

Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide

Unknown status·—·Phase 2·NCT03475758·100 enrolled

25 more indications

Breast Neoplasms2 trials

preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women With Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07287098·600 enrolled

A Phase 2 Trial of (Z)-Endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women With ER+, HER2-, Breast Cancer

Active, not recruiting·AAtossa Therapeutics, Inc.·Phase 2·NCT05607004·87 enrolled

Adjuvant1 trial

Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women

Unknown status·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 3·NCT02914158·680 enrolled

Salivary Gland Carcinoma1 trial

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Active, not recruiting·NNational Cancer Center Hospital East·Phase 2·NCT05694819·56 enrolled

Atrophy1 trial

Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy

Completed·RRamathibodi Hospital·Phase 4·NCT00851461·10 enrolled

Lymphoma1 trial

Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients

Enrolling by invitation·—·Phase 2·NCT04536467·80 enrolled

Hormone Therapy1 trial

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Recruiting·NNational Taiwan University Hospital·Phase 2·NCT05720260·42 enrolled

Endocrine Therapy1 trial

Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)

Active, not recruiting·JJules Bordet Institute·Phase 2·NCT04551495·65 enrolled

Androgen Deprivation Therapy1 trial

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Completed·MMedical College of Wisconsin··NCT02366494·42 enrolled

Metabolic Syndrome1 trial

Testosterone Effects on Men With the Metabolic Syndrome

Withdrawn·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00382057·72 enrolled

Neoadjuvant Therapy1 trial

Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate

Unknown status·WWest China Hospital·Phase 2·NCT04736108·50 enrolled

Postmenopausal Women1 trial

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Completed· Novartis logo

Novartis·Phase 3·NCT02941926·3,246 enrolled

Chemotherapy1 trial

Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)

Completed·GGBG Forschungs GmbH·Phase 2·NCT00196846·62 enrolled

Uterine leiomyoma1 trial

Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin

Terminated·UUniversity of Sao Paulo·Phase 4·NCT01738724·14 enrolled

Ovarian Function1 trial

Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women

Unknown status·KKorean Breast Cancer Study Group·Phase 3·NCT00912548·1,234 enrolled

Menopausal Women1 trial

Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women

Unknown status·SSamsung Medical Center·Phase 2·NCT01266213·147 enrolled

Depression1 trial

Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression

Completed·GGitte Moos Knudsen·N/A·NCT02661789·63 enrolled

Ovarian Reserve1 trial

Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients

Active, not recruiting·PPeking University People's Hospital··NCT02430103·349 enrolled

Phase II1 trial

Phase II Dutasteride in Combination With CAB vs CAB in SDC

Recruiting·RRadboud University Medical Center·Phase 2·NCT05513365·26 enrolled

Metastatic Breast Cancer1 trial

A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study

Active, not recruiting· Novartis logo

Novartis·Approved·NCT05161195·134 enrolled

Early Breast Cancer1 trial

A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)

Recruiting· Novartis logo

Novartis·Phase 3·NCT05827081·1,400 enrolled

Musculoskeletal Injury1 trial

Musculoskeletal Resiliency and Adaptation to Sex Steroid Suppression and Replacement During Multi-Stressor Training

Recruiting·BBradley Nindl·Approved·NCT06455969·120 enrolled

Anatomic Stage III Breast Cancer AJCC v81 trial

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02115282·608 enrolled

Recurrent Castration-Sensitive Prostate Carcinoma1 trial

MC230502 Dynamic Investigator Initiated Enterprise (DIVINE) in Prostate Cancer

Recruiting·MMayo Clinic·Phase 2·NCT06378866·532 enrolled

Anatomic Stage I Breast Cancer AJCC v81 trial

Phase 2 Interventional Trial of Ovarian Function Suppression for Breast Cancer (OFS)

Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT07158021·75 enrolled

Unspecified1 trial

Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting·PProf. Wolfgang Janni·Phase 3·NCT02344472·271 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 29, 1989

ZOLADEX

NDA NDA019726

Jan 11, 1996

ZOLADEX

NDA NDA020578

Sources

References

[1]
ClinicalTrials.gov — 106 trial records for Goserelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Zoladex drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Goserelin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Goserelin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020578). U.S. Food & Drug Administration.
[6]
SEC EDGAR — TerSera Therapeutics LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Gonadotropin-Releasing Hormone Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: TTerSera Therapeutics LLC

Related News